Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).

被引：1
|
作者：
Ferrarotto, Renata
Mata, Javier
Mott, Frank
Bhosale, Priya
Rubin, M. Laura
Altan, Mehmet
Dervin, Shannon
Yun, Cindy
Yao, James C.
Halperin, Daniel M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Div Canc Med, Houston, TX 77030 USA
[3] Genentech Inc, San Francisco, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e21006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21006
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
    Okuno, Masayuki
    Ishii, Takamichi
    Ichida, Akihiko
    Soyama, Akihiko
    Takemura, Nobuyuki
    Hirono, Seiko
    Eguchi, Susumu
    Hasegawa, Kiyoshi
    Sasaki, Yasuharu
    Uemura, Kohei
    Kokudo, Norihiro
    Hatano, Etsuro
    BMC CANCER, 2023, 23 (01)
  • [32] Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab
    Masayuki Okuno
    Takamichi Ishii
    Akihiko Ichida
    Akihiko Soyama
    Nobuyuki Takemura
    Seiko Hirono
    Susumu Eguchi
    Kiyoshi Hasegawa
    Yasuharu Sasaki
    Kohei Uemura
    Norihiro Kokudo
    Etsuro Hatano
    BMC Cancer, 23 (1)
  • [33] Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
    Cai, Q.
    Zou, Q.
    Zhang, Y.
    Xia, Y.
    Liu, P.
    Su, N.
    Wang, J.
    Tian, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S579 - S579
  • [34] Postoperative adjuvant tislelizumab plus lenvatinib and capecitabine for biliary tract cancer: Interim results of a prospective, single-arm, phase II study
    Feng, Y.
    Zhang, N.
    Zhao, Y.
    Pan, Q.
    Mao, A.
    Zhu, W.
    Lin, Z.
    Wang, L.
    Wang, Y. L.
    Zhou, J.
    Zhang, T.
    Wang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S119 - S119
  • [35] Modified-dose capecitabine plus bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study
    Hsu, C.
    Yang, T.
    Hsu, C.
    Toh, H.
    Epstein, R. J.
    Hsiao, L.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] TACE combined with the intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: A prospective, single-arm, phase II study
    Mu, Maoyuan
    Fu, Xiaobo
    Qi, Han
    Jiang, Weiwei
    Chen, Zixiong
    Gao, Fei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] B-TREUH results: A single-arm phase II pilot study of euthyroid hypothyroxinemia in metastatic breast carcinoma
    Trehan, Shruti
    Cheng, Suzan S.
    Rawal, Anisha
    Amos, Mary
    Collins, Kathleen
    Hercbergs, Aleck
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial
    Liu, Dongming
    Mu, Han
    Liu, Changfu
    Zhang, Weihao
    Cui, Yunlong
    Wu, Qiang
    Zhu, Xiaolin
    Fang, Feng
    Zhang, Wei
    Xing, Wenge
    Li, Qiang
    Song, Tianqiang
    Lu, Wei
    Li, Huikai
    NEOPLASMA, 2023, 70 (06) : 811 - 818
  • [39] Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study
    Dumitriu, Bogdan
    Ito, Sawa
    Feng, Xingmin
    Stephens, Nicole
    Yunce, Muharrem
    Kajigaya, Sachiko
    Melenhorst, Joseph J.
    Rios, Olga
    Scheinberg, Priscila
    Chinian, Fariba
    Keyvanfar, Keyvan
    Battiwalla, Minoo
    Wu, Colin O.
    Maric, Irina
    Xi, Liqiang
    Raffeld, Mark
    Muranski, Pawel
    Townsley, Danielle M.
    Young, Neal S.
    Barrett, Austin J.
    Scheinberg, Phillip
    LANCET HAEMATOLOGY, 2016, 3 (01): : E22 - E29
  • [40] A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.
    Pili, Roberto
    Haas, Naomi B.
    Monk, Paul
    Logan, Theodore F.
    Narayan, Vivek
    Burney, Heather
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345